***De novo* variants in *SNAP25* cause an early onset developmental and epileptic encephalopathy**

**Supplemental Data**

Chiara Klöckner, Heinrich Sticht, Pia Zacher, Bernt Popp, Dewi P. Bakker, Katy Barwick, Michaela V. Bonfert, Eva H. Brilstra, CareRare Canada Consortium, Wendy K. Chung, Angus J. Clarke, Patrick Devine, Jennifer Friedman, Alyssa Gates, Gabriella Horvath, Jennifer Keller-Ramey, Boris Keren, Manju A. Kurian, Virgina M. Lee, Kathleen A. Leppig, Johan Lundgren, Marie T. McDonald, Amy McTague, Heather C. Mefford, Cyril Mignot, Mohamad Mikati, Caroline Nava, F. Lucy Raymond, Julian R. Sampson, Alba Sanchis-Juan, Vandana Shashi, Joseph T.C. Shieh, Marwan Shinawi, Anne Slavotinek, Tommy Stödberg, Nicholas Stong, Jennifer A. Sullivan, Ashley C. Taylor, Tomi L. Toler, Marie-José van den Bogaard, Saskia N. van der Crabben, Koen van Gassen, Richard H. van Jaarsveld, Jessica van Ziffle, Alexandrea Wadley, Matias Wagner, Saskia B. Wortmann, Rikke S. Møller, Johannes R. Lemke and Konrad Platzer

Corresponding Author

Konrad Platzer, MD

Konrad.platzer@medizin.uni-leipzig.de

**Supplemental Tables**

Table S1. Detailed clinical information of all individuals with (likely) pathogenic *de novo* variants in *SNAP25* (Excel-file)

Table S2. Detailed clinical information of all individuals with variants of unknown significance in *SNAP25* (Excel-file)

Table S3.1. Information on variant location, predicted structural effects and classification according to the ACMG criteria of all (likely) pathogenic variants in *SNAP25 (*NM\_130811.4)*.*

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **individual** | **chr20: g.** | **Reference allele (Ref)** | **Alternate allele (Alt)** | **c.** | **p.** | **Origin** | **Domain** | **Main structural effect(s)** | **ACMG criteria** |  |
| 11 | 10265375 | A | G | c.118A>G | p.(Lys40Glu) | de novo | t-SNARE coiled coil homology 1 | Electrostatic repulsion with Glu37/Asp41 (SNAP25) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 2/31/4 | 10265384 | G | C | c.127G>C | p.(Gly43Arg) | de novo | t-SNARE coiled coil homology 1 | Steric clashes with Leu160 (SNAP25) and Phe216 (Syntaxin) | PS2, PS4\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 52 | 10265399 | G | T | c.142G>T | p.(Val48Phe) | de novo | t-SNARE coiled coil homology 1 | Steric clash with Leu198 (αSNAP) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 63 | 10265406 | T | C | c.149T>C | p.(Leu50Ser) | de novo | t-SNARE coiled coil homology 1 | Reduced packing with Met167/Ile171 (SNAP25) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 7 | 10273815 | T | G | c.170T>G | p.(Leu57Arg) | de novo | t-SNARE coiled coil homology 1 | Steric clash with Gln174 (SNAP25) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 84 | 10273845 | T | A | c.200T>A | p.(Ile67Asn) | de novo | t-SNARE coiled coil homology 1 | Reduced packing with Val241(Syntaxin) | PS3, PS2\_Moderate, PM2, PP2, PP3 | pathogenic |
| 9/10 | 10273857 | T | C | c.212T>C | p.(Met71Thr) | de novo | t-SNARE coiled coil homology 1 | Reduced packing with Ile192 (SNAP25) and Val244 (Syntaxin) | PS2\_Moderate, PS4\_Supporting, PM2, PP2, PP3 | likely pathogenic |
| 115 | 10280004 | G | T | c.496G>T | p.(Asp166Tyr) | de novo | t-SNARE coiled coil homology 2 | Steric clashes with Leu197(αSNAP) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 12 | 10280005 | A | G | c.497A>G | p.(Asp166Gly) | de novo | t-SNARE coiled coil homology 2 | Destabilizes helix in SNAP25 | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 13 | 10280029 | A | C | c.521A>C | p.(Gln174Pro) | de novo | t-SNARE coiled coil homology 2 | Disrupts helix in SNAP25 | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 14 | 10286799 | T | C | c.575T>C | p.(Ile192Thr) | de novo | t-SNARE coiled coil homology 2 | Reduced packing with Met71(SNAP25) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 15 | 10286817 | G | C | c.593G>C | p.(Arg198Pro) | de novo | t-SNARE coiled coil homology 2 | Disrupts helix in SNAP25 | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 16 | 10286820 | C | G | c.596C>G | p.(Ala199Gly) | de novo | t-SNARE coiled coil homology 2 | Destabilizes SNAP25 | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 17 | 10286820 | C | T | c.596C>T | p.(Ala199Val) | de novo | t-SNARE coiled coil homology 2 | Steric clashes with Phe77(VAMP2) | PS2\_Moderate, PM2, PP2, PP3 | likely pathogenic |
| 18 | 10258376 | T | G | c.114+2T>G | p.(?) | de novo | - | Complete unfolding of SNAP25 expected | PVS1\_Moderate, PS2\_Moderate,PM2, PP3 | likely pathogenic |
| 19/201 | 10280028 | C | T | c.520C>T | p.(Gln174\*) | de novo | - | Unfolding of SNAP25 expected | PVS1\_Moderate, PS2, PS4\_Supporting, PM2 | likely pathogenic |

Table S3.2. Information on variant location, predicted structural effects and classification according to the ACMG criteria of all variants of unknown significance in *SNAP25 (*NM\_130811.4)*.*

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **individual** | **chr20: g.** | **Ref** | **Alt** | **c.** | **p.** | **Origin** | **Domain** | **main structural effect(s)** | **ACMG** |  |
| V1 | 10258352 | G | A | c.92G>A | p.(Arg31His) | unknown | t-SNARE coiled coil homology 1 | Interaction with Glu206 (Syntaxin) disrupted, altered interaction with Glu240 (αSNAP) | PM2, PP2, PP3 | VUS |
| V2/V36 | 10273821 | G | C | c.176G>C | p.(Arg59Pro) | paternal mosaic (50-100%) | t-SNARE coiled coil homology 1 | Disrupts helix in SNAP25 and interaction with Thr118 (αSNAP) | PM2, PP2, PP3 | VUS |
| V4 | unknown | G | A | c.220G>A | p.(Ala74Thr) | maternal | t-SNARE coiled coil homology 1 | Only weak effects | PM2, PP2, PP3 | VUS |
| V5 | 10277695 | G | A | c.404G>A | p.(Arg135His) | de novo |  | Thr138 phosphorylation likely affected | PS2\_Moderate | VUS |
| V6 | 10279972 | G |  | c.464delG | p.(Gly155Alafs\*84) | maternal |  | complete unfolding of SNAP25 expected | PVS1\_Moderate, PM2 | VUS |
| V7 | 10286825 | A | T | c.601A>T | p.(Lys201\*) | unknown |  | Disrupts packing of Met202-Leu81 (SNAP25) | PVS1\_Moderate, PM2 | VUS |

Table S4.1. *In silico* prediction of all (likely) pathogenic missense variants and conservation of affected amino acids in *SNAP25 (*NM\_130811.4)*.*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Indi-vidual** | **chr20: g.** | **Ref** | **Alt** | **c.** | **p.** | **CADD 1.4** (Kircher et al.)7 | **REVEL** (Ioannidis et al.)8 | **Mutation Taster2** (Schwarz et al.)9 | **M-CAP 1.3** (Jagadeesh et al.)10 | **Polyphen-2 v2.2.2** (Adzhubei et al.)11 | **GERP++** (Cooper et al.)12 | **Conser-vation** | **Absent from GnomAD** | **distance to next missense (#) \*** |
| 1 | 10265375 | A | G | c.118A>G | p.(Lys40Glu) | 26,8 | 0,474 | DC | T | PrD | 5,8 | high, fruitfly | yes | -5 (1) |
| 2/3/4 | 10265384 | G | C | c.127G>C | p.(Gly43Arg) | 31 | 0,844 | DC | D | PrD | 5,8 | high, fruitfly | yes | -8 (1) |
| 5 | 10265399 | G | T | c.142G>T | p.(Val48Phe) | 31 | 0,781 | DC | D | PrD | 5,07 | high, fruitfly | yes | -13 (1) |
| 6 | 10265406 | G | T | c.149T>C | p.(Leu50Ser) | 34 | 0,707 | DC | D | PrD | 5,8 | high, C. elegans | yes | +14 (1) |
| 7 | 10273815 | T | G | c.170T>G | p.(Leu57Arg) | 27,2 | 0,814 | DC | D | PoD | 5,9 | high, C. elegans | yes | +7 (1) |
| 8 | 10273845 | T | A | c.200T>A | p.(Ile67Asn) | 27,3 | 0,86 | DC | D | PrD | 5,9 | high, fruitfly | yes | -3 (1) |
| 9/10 | 10273857 | T | C | c.212T>C | p.(Met71Thr) | 23,7 | 0,556 | DC | D | PoD | 5,9 | high, fruitfly | yes | +5 (1) |
| 11 | 10280004 | G | T | c.496G>T | p.(Asp166Tyr) | 33 | 0,658 | DC | D | PrD | 6,17 | high, C. elegans | yes | +1 (1) |
| 12 | 10280005 | A | G | c.497A>G | p.(Asp166Gly) | 34 | 0,683 | DC | D | PrD | 6,17 | high, C. elegans | yes | +1 (1) |
| 13 | 10280029 | A | C | c.521A>C | p.(Gln174Pro) | 33 | 0,876 | DC | D | PrD | 6,17 | high, C. elegans | yes | +2 (1) |
| 14 | 10286799 | T | C | c.575T>C | p.(Ile192Thr) | 32 | 0,656 | DC | D | PrD | 5,94 | high, zebrafish | yes | +2 (1) |
| 15 | 10286817 | G | C | c.593G>C | p.(Arg198Pro) | 29,1 | 0,52 | DC | D | PoD | 5,94 | high, fruitfly | yes | -2 (1) |
| 16 | 10286820 | C | G | c.596C>G | p.(Ala199Gly) | 29,8 | 0,669 | DC | T | PrD | 5,94 | high, fruitfly | yes | -3 (1) |
| 17 | 10286821 | C | T | c.596C>T | p.(Ala199Val) | 29,7 | 0,688 | DC | T | PrD | 5,94 | high, fruitfly | yes | -3 (1) |

Table S4.2. *In silico* prediction13 of the (likely) pathogenic splice site variant in *SNAP25 (*NM\_130811.4)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Indi-vidual** | **chr20: g.** | **Ref** | **Alt** | **c.** | **p.** | **Splicing prediction** | **MaxEnt**14 | **NNSPLICE**15 | **SSF**16 |
| 18 | 10277728 | T | G | c.114+2T>G | p.? | The splice donor site is completey abolished (MAxEntScan, NNSPLICE, SpliceSiteFinder-like) | -100.0% | -100.0% | -100.0% |

Table S4.3. *In silico* prediction of all missense variants classified as variants of unknown significance and conservation of affected amino acids in *SNAP25 (*NM\_130811.4)*.*

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Individual** | **chr20: g.** | **Ref** | **Alt** | **c.** | **p.** | **CADD 1.4** (Kircher et al.)7 | **REVEL** (Ioannidis et al.)8 | **Mutation Taster2** (Schwarz et al.)9 | **M-CAP 1.3** (Jagadeesh et al.)10 | **Polyphen-2 v2.2.2** (Adzhubei et al.)11 | **GERP++** (Cooper et al.)12 | **Conservation** | **Absent from GnomAD** | **distance to next missense (#)** |
| V1 | 10258352 | G | A | c.92G>A | p.(Arg31His) | 33 | 0,58 | DC | D | PrD | 5,78 | high, fruitfly | yes | ± 0 (1) |
| V2/3 | 10273821 | G | C | c.176G>C | p.(Arg59Pro) | 29,9 | 0,675 | DC | D | PrD | 5,9 | high, fruitfly | yes | +5 (1) |
| V4 | ? | G | A | c.220G>A | p.(Ala74Thr) | 25,4 | 0,514 | DC | D | PrD | 5,9 | high, fruitfly | yes | +2 (1) |
| V5 | 10277695 | G | A | c.404G>A | p.(Arg135His) | 25,7 | 0,378 | DC | T | B | 5,86 | high, zebrafish | no | ± 0 (5) |

Conservation was evaluated considering the following species: Homo sapiens, Pan troglodytes (chimp), Rattus norvegicus (rat), Mus musculus (mouse), Canis familiaris (dog), Ornithorhynchus anatinus (platypus), Gallus gallus (chicken), Xenopus tropicalis (frog), Tetraodon nigroviridis, Danio rerio (zebrafish), Drosophila melanogaster (fruitfly), Caenorhabditis elegans (C. elegans)

Table S5. Phenotypic overlap of the “SNAREopathies”. Abbreviations: +, association with phenotype; -, no association with phenotype

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Gene** | ***SNAP25*** | ***STXBP1*** | ***STX1B*** | ***VAMP2*** | ***SYT1*** | ***PRRT2*** |
| Phenotype |  | Epileptic encephalopathy, early infantile, 4 | Generalized epilepsy with febrile seizures plus, type 9 | Neurodevelopmental disorder with hypotonia and autistic features with or without hyperkinetic movements | Baker-Gordon syndrome | Convulsions, familial infantile, with paroxysmal choreoathetosis / Episodic kinesigenic dyskinesia 1 / Seizures, benign familial infantile, 2 |
| MIM number |  | 612164 | 616172 | 618760 | 618218 | 602066 / 128200 / 605751 |
| Inheritance | AD | AD | AD | AD | AD | AD |
| **ID/DD** | Yes | Yes | Yes | Yes | Yes | No |
| **Epilepsy** | Yes | Yes | Yes | Yes | No | Yes |
| Early-onset | + | + | + | + | - | + |
| Multiple seizure types | + | + | + | + | - |  |
| Abnormal EEG | + | + | + | + | + | - |
| **Movement Disorder** | Yes | Yes | Yes | Yes | Yes | Yes |
| Muscular hypotonia | + | + | + | + | + | - |
| Ataxia | + | + | + | + | + |  |
| Dystonia | + | + | + | + | + | + |
| Spasticity | + | + |  |  |  |  |
| Tremor | + | + | + |  |  |  |
| Involuntary/ repetitive movements | + |  |  | + | + | + |
| **Further Findings** |  |  |  |  |  |  |
| Brain volume loss | + | + |  |  |  |  |
| CVI | + |  |  | + | + |  |
| ASD | + | + | + | + |  |  |
| Behavioral issues |  | + |  | + | + |  |
| **Comments** |  | Stamberger *et al.*17 used as reference | Variants in *STX1B* contribute to different epilepsy phenotypes, one of them described as a developmental and epileptic encephalopathy18 | Based on the phenotypic description of five individuals19 | Based on the phenotypic description of eleven individuals 20 | Heron *et al.* 21 used as reference |

**Supplemental Figures**

Figure S1: Upset-Plot22 of recurrent phenotypic presentations. Abbreviations: DD/ID = developmental delay/intellectual disability, Sz = seizures, MD = movement disorder, CVI = cortical visual impairment





Figure S2. Phenotypic overlap of the “SNAREopathies”. *STX1B* is listed twice for its different phenotypic presentations.18



**References**

1. Heyne HO, Singh T, Stamberger H, et al. De novo variants in neurodevelopmental disorders with epilepsy. *Nat Genet*. 2018;50(7):1048-1053. doi:10.1038/s41588-018-0143-7

2. Rohena L, Neidich J, Truitt Cho M, et al. Mutation in SNAP25 as a novel genetic cause of epilepsy and intellectual disability. *Rare Dis*. 2013;1:e26314. doi:10.4161/rdis.26314

3. Liang J-S, Wang J-S, Lin L-J, Yang M-T, Hung K-L, Lu J-F. Genetic Diagnosis in Children with Epilepsy and Developmental Delay/Mental Retardation Using Targeted Gene Panel Analysis. *Neuropsychiatry*. 2018;08(05). doi:10.4172/Neuropsychiatry.1000494

4. Shen X-M, Selcen D, Brengman J, Engel AG. Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. *Neurology*. 2014;83(24):2247-2255. doi:10.1212/WNL.0000000000001079

5. Hamdan FF, Myers CT, Cossette P, et al. High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. *The American Journal of Human Genetics*. 2017;101(5):664-685. doi:10.1016/j.ajhg.2017.09.008

6. Fukuda H, Imagawa E, Hamanaka K, et al. A novel missense SNAP25b mutation in two affected siblings from an Israeli family showing seizures and cerebellar ataxia. *J Hum Genet*. 2018;63(5):673-676. doi:10.1038/s10038-018-0421-3

7. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet*. 2014;46(3):310-315. doi:10.1038/ng.2892

8. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *Am J Hum Genet*. 2016;99(4):877-885. doi:10.1016/j.ajhg.2016.08.016

9. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods*. 2010;7(8):575-576. doi:10.1038/nmeth0810-575

10. Jagadeesh KA, Wenger AM, Berger MJ, et al. M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity. *Nat Genet*. 2016;48(12):1581-1586. doi:10.1038/ng.3703

11. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. *Curr Protoc Hum Genet*. 2013;Chapter 7:Unit7.20. doi:10.1002/0471142905.hg0720s76

12. Cooper GM, Stone EA, Asimenos G, et al. Distribution and intensity of constraint in mammalian genomic sequence. *Genome Res*. 2005;15(7):901-913. doi:10.1101/gr.3577405

13. Houdayer C. In silico prediction of splice-affecting nucleotide variants. *Methods Mol Biol*. 2011;760:269-281. doi:10.1007/978-1-61779-176-5\_17

14. Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. *J Comput Biol*. 2004;11(2-3):377-394. doi:10.1089/1066527041410418

15. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. *J Comput Biol*. 1997;4(3):311-323. doi:10.1089/cmb.1997.4.311

16. Zhang MQ. Statistical features of human exons and their flanking regions. *Hum Mol Genet*. 1998;7(5):919-932. doi:10.1093/hmg/7.5.919

17. Stamberger H, Nikanorova M, Willemsen MH, et al. STXBP1 encephalopathy: A neurodevelopmental disorder including epilepsy. *Neurology*. 2016;86(10):954-962. doi:10.1212/WNL.0000000000002457

18. Wolking S, May P, Mei D, et al. Clinical spectrum of STX1B-related epileptic disorders. *Neurology*. 2019;92(11):e1238-e1249. doi:10.1212/WNL.0000000000007089

19. Salpietro V, Malintan NT, Llano-Rivas I, et al. Mutations in the Neuronal Vesicular SNARE VAMP2 Affect Synaptic Membrane Fusion and Impair Human Neurodevelopment. *Am J Hum Genet*. 2019;104(4):721-730. doi:10.1016/j.ajhg.2019.02.016

20. Baker K, Gordon SL, Melland H, et al. SYT1-associated neurodevelopmental disorder: a case series. *Brain*. 2018;141(9):2576-2591. doi:10.1093/brain/awy209

21. Heron SE, Grinton BE, Kivity S, et al. PRRT2 mutations cause benign familial infantile epilepsy and infantile convulsions with choreoathetosis syndrome. *Am J Hum Genet*. 2012;90(1):152-160. doi:10.1016/j.ajhg.2011.12.003

22. Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: Visualization of Intersecting Sets. *IEEE Trans Vis Comput Graph*. 2014;20(12):1983-1992. doi:10.1109/TVCG.2014.2346248